NOA - Neurologische Arbeitsgemeinschaft

Publikationen

Adjuvant stereotactic fractionated radiotherapy to the resection cavity in recurrent glioblastoma - the GlioCave study (NOA-17 - ARO 2016/3 - DKTK ROG trial).

Straube C, Scherb H, Gempt J, Kirschke J, Zimmer C, Schmidt-Graf F, Meyer B, Combs SE.

BMC Cancer 2018;18: 15

Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promotor-hypermethylation - the NCT Neuro Master Match (N²M²) pilot study

Pfaff E, Kessler T, Balasubramanian GP, Berberich A, Schrimpf D, Wick A, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Capper D, Schenkel I, Eisenmenger A, Dettmer S, Brors B, Platten M, Pfister SM, von Deimling A, Jones DTW, Wicke W, Sahm F.

Neuro Oncol 2018;20: 826 – 837

Multicenter pilot study of radio-chemotherapy as first-line treatment for adults with medulloblastoma (NOA-07)

Dagmar D, Proescholt M, Reinert C, Pietsch T, Jones DTW, Pfister SM, Hattingen E, Seidel C, Dirven L, Luerding R, Reijneveld J, Warmuth-Metz M, Bonsanto M, Bremer M, Combs S, Rieken S, Herrlinger U, Kuntze H, Mayer-Steinacker R, Moskopp D, Schneider T, Beringer A, Schlegel U, Stummer W, Welker H, Weyerbrock A, Paulsen F, Rutkowski S, Weller M, Wick W, Kortmann RD, Bogdahn U, Hau P.

Neuro Oncol. 2018;20: 400 - 410

Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnoses, MGMT-nonmethylated glioblastoma

Schäfer N, Proescholdt M, Steinbach JP, Weyerbrock A, Hau P, Grauer O, Goldbrunenr R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Grau S, Hänel M, Schnell O, Krex D, Vajkoczy P, Tabatabai G, Mack F, Schaub C, Tzaridis T, Nießen M, Kebir S, Leutgeb B, Urbach H, Belka C, Stummer W, Glas M, Herrlinger U.

Neuro Oncol 2018;20: 975 - 985

Tumor growth patterns of MGMT-non-methylated glioblastoma in the randomized GLARIUS trail.

Schaub C, Kebir S, Junold N, Hattingen E, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Niessen M, Mack F, Stuplich M, Tzaridis T, Bähr O, Kortmann RD, Schlegel U, Schmidt-Graf F, Rohde V, Braun C, Hänel M, Sabel M, Gerlach R, Krex D, Belka C, Vatter H, Proescholdt M, Herrlinger U, Glas M.

J Cancer Clin Oncol. 2018;144: 1581 - 1589

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017;390: 1645 - 1653

Phase III trial of CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma patients: the CeTeG/NOA-09 trial.

Herrlinger U, Tzaridis T, Mack F et al.

Neuro Oncol 2017;19 (suppl. 6) vi13 - vi 14

Bevacizumab plus Irinotecan versus Temozolomide in newly diagnosed 06-Methylguanine-DNA methyltransferase nonmethylated Glioblastoma: The randomized GLARIUS Trial.

Herrlinger U, Schäfer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, Friedrich F, Rohde V, Ringel F, Schlegel U, Sabel M, Ronellenfitsch MW, Uhl M, Maciaczyk J, Grau S, Schnell O, Hänel M, Krex D, Vajkoczy P, Gerlach R, Kortmann RD, Mehdorn M, Tüttenberg J, Mayer-Steinacker R, Fietkau R, Brehmer S, Mack F, Stuplich M, Kebir S, Kohnen R, Dunkl E, Leutgeb B, Proescholdt M, Pietsch T, Urbach H, Belka C, Stummer W, Glas M.

J Clin Oncol 2016;34: 1611 - 1919

Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial.

Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, Sabel MC, Herrlinger U, Ketter R, Schlegel U, Marosi C, Reifenberger G, Wick W, Tonn JC, Wirsching HG.

Neuro Oncol. 2016;18: 549 - 556

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.

Wick W, Roth P, Hartmann C, Hau P, Nakamura M, Stockhammer F, Sabel MC, Wick A, Koeppen S, Ketter R, Vajkoczy P, Eyupoglu I, Kalff R, Happold C, Galldiks N, Schmidt-Graf F, Bamberg M, Reifenberger G, Platten M, von Deimling A, Meisner C, Wiestler B, Weller M; Neurooncology Working Group (NOA) of the German Cancer Society.

Neuro Oncol. 2016;18: 1529 - 1537

Differently regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients.

Roth P, Keller A, Hoheisel JD, Codo P, Bauer AS, Backes C, Leidnger P, Meese E, Thiel E, Korfel A, Weller M.

Eur J Cancer 2015;51: 382 - 390

MGMT Promotor Methylation is a strong prognostic biomarker for benefit from dose-intensified Temozolomide rechallenge in progressive Glioblastoma: The DIRECTOR Trail.

Weller M, Tabatabai G, Kästner B, Felsberg J, Steinbach JP, Wick A, Schnell O, Hau P, Herrlinger U, Sabel MC, Wirsching HG, Ketter R, Bähr O, Platten M, Tonn JC, Schlegel U, Marosi C, Goldbrunner R, Stupp R, Homicsko K, Pichler J, Nikkah G, Meixensberger J, Vajkoczy P, Kollias S, Hüsing J, Reifenberger G, Wick W; DIRECTOR Studiy Group

Clin Cancer Res 2015;21: 2057 - 2064

Molecullar classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015;129: 679 - 693

Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial.

Kreher S, Strehlow F, Martus P, Hertenstein B, Röth A, Birnbaum T, Griesinger F, Rauch M, Kanz L, Thiel E, Weller M, Korfel A.

Ann Hematol. 2015;94: 409 - 414

Whole brain irradiation with hippocampal sparing and dose escalation on multiple brain metastases: Local tumour control and survival.

Oehlke O, Wucherpfennig D, Fels F, Frings L, Egger K, Weyerbrock A, Prokic V, Nieder C, Grosu AL.

Strahlenther Onkol. 2015;191: 461 - 469

Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promotor methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.

Wiestler B, Capper D, Hovestadt V, Sill M, Jones DTW, Hartmann C, Felsberg J, Platten M, Feiden W, Keyvani K, Pfister SM, Wiestler OD, Meyermann R, Reifenberger G, Pietsch T, von Deimling A, Weller M, Wick W.

Neuro Oncology 2014;16: 1630 - 1638

Integrated DNA methylation and copy-number profiling identifies three clinically and biologically relevant groups of anaplastic glioma.

Wiestler B, Capper D, Sill M, Jones DTW, Hovestadt V, Sturm D, Koelsche C, Bertonie A, Schweizer L, Korshunov A, Weiß EK, Schliesser MG, Radbruch A, Herold-Mende, C, Roth P, Unterberg A, Hartmann C, Pietsch T, Reifenberger G, Lichter P, Radlwimmer B, Platten M, Pfister SM, von Deimling A, Weller M, Wick W.

Acta Neuropathol 2014;128: 561 - 571

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors wit better prognosis.

Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W.

Acta Neuropathol. 2013;126: 443 - 451

Distribution of TERT promotor mutations in pediatric and adult tumors of the nervous system.

Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, Meyer J, Mawrin C, Hartmann C, Mittelbronn M, Platten M, Brokinkel B, Seiz M, Herold-Mende C, Unterberg A, Schittenhelm J, Weller M, Pfister S, Wick W, Korshunov A, von Deimling A.

Acta Neuropathol. 2013;126: 907 - 915

Malignant astrocytoms of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; Neuro-oncology Working Group (NOA) of the German Cancer Society.

Neuro Oncol. 2013;15:1017 - 1026

MGMT testing-the challenges for biomarker-based glioma treatment.

Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G.

Nat Rev Neurol. 2014;10: 372 - 385

Prognostic or predictive value of MGMT promotor methylation in gliomas depends on IDH1 mutation.

Wick W, Meisner C, Hentschel B, Platten M, Schilling A, Wiestler B, Sabel MC, Koeppen S, Ketter R, Weiler M, Tabatabai G, von Deimling A, Gramatzki D, Westphal M, Schackert G, Loeffler M, Simon M, Reifenberger G, Weller M.

Neurology 2013;81: 1515 - 1522

[(18)F]FET-PET Imaging for treatment and response monitoring of radiation therapy in malignant glioma patients - a review.

Götz I, Grosu AL.

Front Oncol. 2013;3: 104

Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1.

Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, Röth A, Kaus S, Thiel E, Korfel A, Weller M.

Neurology 2012;79: 890 - 896

Pathogenesis and management of primary CNS lymphoma.

Roth P, Korfel A, Martus P, Weller M.

Expert Rev Anitcancer Ther. 2012;12: 623 - 633

Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial.

Korfel A, Weller M, Mrtus P, Roth P, Klasen HA, Roeth A, Rauch M, Hertenstein B, Fischer T, Hundsberger T, Leithäuser M, Birnbaum T, Kirchen H, Mergenthaler HG, Schubert J, Berdel W, Birkmann J, Hummel M, Thiel E, Fischer L.

Ann Oncol. 2012;23: 2374 - 2380

Surgery of primary CNS lymphoma? Challenging a paradigm.

Weller M, Martus P, Roth P, Thiel E, Korfel A, German PCNSL Group.

Neuro Oncol. 2012;14: 1481 - 1481

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.

Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs SE, Vesper J, Braun C, Meixensberger J, Ketterr R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of Neuro-oncology Working Group (NAO) of German Cancer Society.

Lancet Oncol. 2012;13: 707 - 715

An interindividual comparison of O-(2-[(18)F]Fluorethyl)-L-Tyrosine (FET)- and L-[Methyl-(11)C]Methionine (MET)-PET in patients with brain gliomas and metastases.

Grosu AL, Astner ST, Riedel E, Nieder C, Wiedenmann N, Heinemann F, Schwaiger M, Molls M, Wester HJ, Weber WA.

Int J Radiat Oncol 2011;81: 1049 - 1058

NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.

Glas M, Bähr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M, Simon M, Urbach H, Steinbach JP, Rieger J, Fimmers R, Bamberg M, Nägele T, Reifenbergerg G, Weller M, Herrlinger U; Neuro-oncology Group of the German Cancer Society.

Ann Neurol. 2011;70: 445 - 453

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).

Grauer O, Pascher C, Hartmann C, Zeman F, Weller M, Proescholdt M, Brawanski A, Pietsch T, Wick W, Bogdahn U, Hau P.

J Neurooncol 2011;105: 671

High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trail.

Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bambert M, Weller M.

Lancet Oncol. 2010;11: 1036 - 1047

Patients with IDH1 wild type anaplastic astrocytoms exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of glioamas.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphall M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.

Acta Neuropathol. 2010;120: 707-718

PET for radiation treatment planning of brain tumors.

Grosu AL, Weber WA.

Radiother Oncol. 2010;96: 325 - 327

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine and vincristine or temozolomide.

Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stockhammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R, Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD, Ernemann U, Bamberg M, Reifenberger G, von Deimling A, Weller M.

J Clin Oncol. 2009;27: 5874 - 5880

NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.

Herrlinger U, Küker W, Uhl M; Blaicher HP, Karnath HO, Kanz L, Bamberg M, Weller M; Neuro-Oncology Working Group of the German Cancer Society

Ann Neurol 2005;57: 843 - 847

Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Weller M, Müller B, Koch R, Bamberg M, Krauseneck P; Neuro-Oncology Working Group of the German Cancer Society

J Clin Oncol 2003;21: 3276 - 3284

German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.

Herrlinger U, Schabet M, Brugger W, Kortmann RD, Küker W, Deckert M, Engel C, Schmeck-Lindenau HJ, Mergenthaler HG, Krauseneck P, Benöhr C, Meisner C, Wiestler OD, Dichgans J, Kanz L, Bamberg M, Weller M.

Ann Neurol 2002;51: 247 - 252.